TABLE 1.

A. fumigatus clinical isolates from Transplant recipients and nontransplant patients

Patient group and isolateTransplant or underlying diseaseImmunosuppressant(s) patient receiving (no. of days received when culture obtained)Antifungal prophylaxisSite of IATreatment of IAaPatient outcome
Transplant recipients
    1HeartCsA (75), mycophenolateAmBPulmonaryABLC, posaconazoleAlive
    2Double lungFK506 (90), azathioprineItraconazolePulmonaryABLCAlive
    3LiverFK506 (21)NonePulmonaryABLCDied
    4Liver (2nd)FK506 (36)NoneDisseminatedL-AmBDied
    5Liver or kidneyFK506 (25)NonePulmonaryABLCAlive
    6Single lungFK506 (80)NonePulmonaryABLC, caspofunginDied
Nontransplant patients
    1AMLbNoneNonePulmonaryAmBAlive
    2CompetentNoneNoneOsteomyelitisAmBAlive
    3CompetentNoneNoneEndocarditisN/ADied
    4SarcoidosisNoneNoneDisseminatedAmBDied
    5Lung cancerNoneNoneParavertebralAmB, itraconazoleDied
    6CompetentNoneNoneOsteomyelitisAmBN/A
  • a ABLC, amphotericin B lipid complex; L-AmB, liposomal amphotericin B; AmB, amphotericin B; NA, data unknown.

  • b AML, acute myelogenous leukemia.